A randomized, double-blind, controled phase 3 study of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell carcinoma of intermediate to poor risk

  • Gurney, Howard (Primary Chief Investigator)
  • Butala, Radhika (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Parshionikar, Abhijit (Clinical Trial Unit Staff)
  • Rajasekharan Nair, Archana (Clinical Trial Unit Staff)

Project: Other

Project Details

Short titleXL184-313
AcronymCOSMIC
StatusFinished
Effective start/end date2/10/19 → 11/07/24